6th Annual Liquid Biopsy for Precision Oncology Summit

Memo

In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements towards the development of more effective and accessible precision oncology treatments.That's why the 6th Liquid Biopsy for Precision Oncology Summit will take place digitally this February, providing you with a valuable industry touchpoint to network, collaborate and learn directly from your peers at an exciting time for precision medicine.As industry's most comprehensive liquid biopsy meeting, unite with 250+ key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.Explore how a breadth of methods including ddPCR, single-cell genotypic and phenotypic analysis, in addition to pan-cancer, comprehensive NGS and tumor-informed assays are enabling detection screening, earlier diagnosis, resistance and recurrence monitoring - in turn facilitating quicker and more informed treatment decision-making in precision drug development.Join to witness first-hand the clinical utility of ctDNA, cfDNA, miRNA and CTC analysis in the precision oncology pipelines of 30+ scientific and commercial biopharma and academic experts successfully advancing immunotherapy and targeted candidates toward patients.Utilize your prime opportunity to meet diverse stakeholders, in person, and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.A crucial date on the precision oncology's industry calendar - It's not to be missed!URLs:Tickets: https://go.evvnt.com/924429-2?pid=5569Brochure: https://go.evvnt.com/924429-3?pid=5569Prices:Conference - Commercial Vendor: USD 3199.0,Conference - Technical Vendor: USD 2099.0,Conference - Drug Developer or Academic: USD 0.5Speakers: Andrew Allen, President, Chief Executive Officer and Co-Founder, Gritstone bio, Ajay Goel, Professor and Chair, Department of Molecular Diagnostics and Experimental Therapeutics, City of Hope, Arvind Dasari, Associate Professor, Department of Gastrointestinal Medical Oncology; Division of Cancer Medicine, MD Anderson Cancer Center, Benoit Destenaves, Executive Director, Head of Biomarkers and Companion Diagnostics, H3 Biomedicine, Dana Connors, Scientific Program Manager, Cancer Research Partnerships, Foundation for the National Institutes of Health, Darren Hodgson, Global Project Leader and Site Head Translational Medicine, AstraZeneca Oncology, David Gandara, Professor, Director, Thoracic Oncology Program; Chief Medical Officer, UC Davis Comprehensive Cancer Center; International Society for Liquid Biopsy, Fernando Cruz-Guilloty, Scientific Director, Oncology Diagnostics, Janssen, George Vasmatzis, Co Director - Biomarker Discovery Program, Mayo Clinic, Harris S. Soifer, Executive Director, Clinical Biomarkers and Companion Diagnostics, Kura Oncology, Jean-Francois Martini, Senior Director, Translational Oncology Lead, Global Product Development, Pfizer, Jill Walker, Head Early Disease Detection Diagnostics, Oncology Precision Medicine, AstraZeneca, Jonathan Beer, Global Precision Medicine Strategic Intelligence Lead, Novartis, Julie Ramage, Director of Precision Medicine Quality Initiatives and Partnerhips, AstraZeneca, Kelly Shanahan, MD Living with Metastatic, Breast Cancer, Kenna Anderes, Vice President Translational Medicine and Companion Diagnostics, Mirati Therapeutics, Klaus Pantel, Chairman, Institute Director, University Medical Center Hamburg-Eppendorf, Koustubh Ranade, Head of Translational Medicine, Immunocore, Lauren Leiman, Executive Director, BloodPAC, Libby Barksdale, Director of Regulatory Affairs and Scientific Policy, LUNGevity Foundation, Marjorie Petty, Senior Director, Operations and Medical Development, Spectrum Pharmaceuticals, Martin Treder, Chief Scientific Officer, Arjuna Therapeutics, Partha Das, Medical Director, CDx and Biomarker Strategy, Amgen, Pashtoon Kasi, Director Colon Cancer Research; Precision Medicine Director for Liquid Biopsy Research, Weill Cornell Medicine; Englander Institute of Precision Medicine, Patrick Gallagher, Chief Actuary, EPIC Insurance Brokers and Consultants, Qu Zhang, Director, Clinical Biomarkers, ImmunoOncology, GlaxoSmithKline, Steven Piccoli, Associate Vice President, Sun Pharma, Steven Rosen, Scientific Innovation Leader In Healthcare, Wyss Institute, Harvard UniversityDate and Time: On Thursday February 10, 2022 at 9:20 am (ends Friday February 11, 2022 at 5:00 pm)